[1]吕学富.石斛养胃汤联合胶体果胶铋干混悬剂及阿莫西林治疗慢性萎缩性胃炎的临床疗效观察[J].医学信息,2021,34(24):163-165.[doi:10.3969/j.issn.1006-1959.2021.24.043]
 LYU Xue-fu.Clinical Efficacy of Shihu Yangwei Decoction Combined with Colloidal Bismuth Pectin for Suspension and Amoxicillin in the Treatment of Chronic Atrophic Gastritis[J].Medical Information,2021,34(24):163-165.[doi:10.3969/j.issn.1006-1959.2021.24.043]
点击复制

石斛养胃汤联合胶体果胶铋干混悬剂及阿莫西林治疗慢性萎缩性胃炎的临床疗效观察()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年24期
页码:
163-165
栏目:
中医中药
出版日期:
2021-12-15

文章信息/Info

Title:
Clinical Efficacy of Shihu Yangwei Decoction Combined with Colloidal Bismuth Pectin for Suspension and Amoxicillin in the Treatment of Chronic Atrophic Gastritis
文章编号:
1006-1959(2021)24-0160-03
作者:
吕学富
(弋阳县人民医院消化肾内科,江西 弋阳 334400)
Author(s):
LYU Xue-fu
(Department of Gastroenterology and Nephrology,Yiyang County People’s Hospital,Yiyang 334400,Jiangxi,China)
关键词:
石斛养胃汤胶体果胶铋干混悬剂慢性萎缩性胃炎胃功能血清炎性因子
Keywords:
Shihu Yangwei decoctionColloidal bismuth pectin for suspensionChronic atrophic gastritisGastric functionSerum inflammatory factors
分类号:
R573.3+2
DOI:
10.3969/j.issn.1006-1959.2021.24.043
文献标志码:
A
摘要:
目的 研究石斛养胃汤联合胶体果胶铋干混悬剂及阿莫西林对慢性萎缩性胃炎胃功能及血清炎性因子影响。方法 选取2019年6月-2021年6月在我院治疗的84例慢性萎缩性胃炎患者为研究对象,采用随机数字表法分为对照组和观察组,各42例。对照组采用胶体果胶铋干混悬剂联合阿莫西林治疗,观察组在对照组基础上联合石斛养胃汤治疗,比较两组临床治疗总有效率、临床症状评分、胃功能指标、血清炎性因子水平以及临床不良反应发生情况。结果 观察组治疗总有效率为92.86%,高于对照组的83.33%(P<0.05);治疗后,观察组临床腹痛、腹胀、嗳气、泛酸各症状评分小于对照组(P<0.05);两组胃泌素-17(G-17)、胃蛋白酶原Ⅰ(PGⅠ)均高于治疗前,且观察组高于对照组(P<0.05);两组血清C反应蛋白(CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平均低于治疗前,且观察组低于对照组(P<0.05);观察组不良反应发生率为4.76%,与对照组的7.14%比较,差异无统计学意义(P>0.05)。结论 石斛养胃汤联合胶体果胶铋干混悬剂及阿莫西林治疗慢性萎缩性胃炎效果理想,可改善胃功能指标,提高治疗效果,降低血清炎性因子水平,减轻临床症状,且不良反应少,是一种有效、安全的联合治疗方案,值得临床加以应用。
Abstract:
Objective To study the effects of Shihu Yangwei decoction combined with colloidal bismuth pectin for suspension and amoxicillin on gastric function and serum inflammatory factors of chronic atrophic gastritis.Methods A total of 84 patients with chronic atrophic gastritis treated in our hospital from June 2019 to June 2021 were selected as the research objects. They were divided into control group and observation group by random number table method, with 42 cases in each group. The control group was treated with colloidal bismuth pectin for suspension and amoxicillin, and the observation group was treated with Shihu Yangwei decoction on the basis of the control group. The total effective rate, clinical symptom score, gastric function index, serum inflammatory factor level and clinical adverse reactions of the two groups were compared.Results The total effective rate of the observation group was 92.86%, which was higher than 83.33% of the control group (P<0.05). After treatment, the scores of clinical abdominal pain, abdominal distension, belching and pantothenic acid in the observation group were lower than those in the control group (P<0.05); gastrin-17 (G-17) and pepsinogen Ⅰ (PGⅠ) in the two groups were higher than those before treatment, and those in the observation group were higher than the control group (P<0.05); the levels of serum C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). The incidence of adverse reactions in the observation group was 4.76%, which was compared with 7.14% in the control group, the difference was not statistically significant (P>0.05).Conclusion Shihu Yangwei decoction combined with colloidal bismuth pectin for suspension and amoxicillin in the treatment of chronic atrophic gastritis has an ideal effect, which can improve the gastric function index and the therapeutic effect, reduce the level of serum inflammatory factors, and relieve clinical symptoms. It is an effective and safe combined treatment scheme with few adverse reactions, which is worthy of clinical application.

参考文献/References:

[1]董安山,潘兆宝,吉华青,等.四联疗法联合胃复春在慢性萎缩性胃炎治疗中的效果观察[J].重庆医学,2017,46(9):1257-1258.[2]方雪峰,洪强,郑志华,等.莫沙比利联合胃炎合剂治疗慢性萎缩性胃炎疗效观察[J].中国急救医学,2017,37(2):100-101.[3]李多,王锐,于永强,等.雷贝拉唑、阿莫西林、克拉霉素联合枳术宽中胶囊治疗老年幽门螺杆菌阳性慢性萎缩性胃炎[J].山东医药,2018,58(3):78-80.[4]王雪萍,徐耀华.阿莫西林联合铋剂对慢性萎缩性胃炎患者血清胃泌素-17及胃蛋白酶原水平影响研究[J].中国生化药物杂志,2016,36(3):64-66.[5]黄金海.石斛养胃汤治疗慢性萎缩性胃炎胃阴不足证57例临床观察[J].中国民族民间医药,2016,25(8):69-71.[6]赵德胜.石斛养胃汤治疗慢性萎缩性胃炎胃阴不足证临床分析[J].中西医结合心血管病电子杂志,2017,5(24):161-164.[7]顾锡桂,蒲应香,邢成文,等.果胶铋联合左氧氟沙星三联疗法对慢性萎缩性胃炎患者血清胃蛋白酶原水平和远期疗效的影响[J].中国医药,2017,12(8):1189-1192.[8]贾渭,蔡波,白宏兴,等.胶体果胶铋颗粒联合替普瑞酮治疗慢性萎缩性胃炎的临床研究[J].现代药物与临床,2016,31(11):1741-1745.[9]翟丽颖,孙海英,郭爱华,等.果胶铋与阿莫西林、克林霉素、奥美拉唑联合治疗慢性萎缩性胃炎患者的临床效果分析[J].航空航天医学杂志,2016,27(6):743-744.[10]王文菊,林丹,李彩娟,等.阿莫西林联合果胶铋治疗慢性萎缩性胃炎的疗效观察[J].现代消化及介入诊疗,2016,21(1):142-144.[11]王雪锋,朱泓霞.阿莫西林联合果胶铋治疗慢性萎缩性胃炎临床探讨[J].中国生化药物杂志,2017,37(9):157-158,160.[12]Li Y,Xia R,Zhang B,et al.Chronic atrophic gastritis:A review[J].J Environ Pathol Toxicol Oncol,2018,37(3):241-259.[13]李争.慢性萎缩性胃炎发病的危险因素与临床治疗效果评价[J].中国现代医生,2018,56(7):31-33.[14]汤茵,钟碧莹,林江英,等.胃蛋白酶原在慢性萎缩性胃炎诊断中的应用价值[J].中国实验诊断学,2018,22(1):21-24.[15]吴玉,蔡敏,张丽,等.石斛养胃汤联合胶体果胶铋干混悬剂及阿莫西林对慢性萎缩性胃炎胃功能及血清炎性因子影响研究[J].中华中医药学刊,2019,37(8):1986-1990.[16]闫寒冰.中医药治疗慢性萎缩性胃炎的临床研究[J].中国医药指南,2020,18(17):206-208.[17]叶建樑.雷贝拉唑、阿莫西林联合胶体果胶铋治疗Hp阳性消化性溃疡的临床研究[J].中国微生态学杂志,2018,30(2):200-202.[18]李阅桥,徐永居.胶体果胶铋胶囊联合自拟益气肠化方改善萎缩性胃炎伴肠上皮化生患者胃功能指标的效果[J].实用临床医药杂志,2019,23(12):75-78,82.[19]李明捷,杜俊英.奥美拉唑联合阿莫西林克拉维酸钾治疗萎缩性胃炎效果及对患者生活质量影响分析[J].山西医药杂志,2018,47(17):12-14.[20]许建平.阿莫西林联合果胶铋治疗慢性萎缩性胃炎的临床疗效研究[J].中西医结合心血管病电子杂志,2017,11(6):102-103.

更新日期/Last Update: 1900-01-01